Business Wire

IL-SHIPPEO

8.4.2024 17:01:33 CEST | Business Wire | Press release

Share
Yamaha Motor Company Selects Shippeo to Enhance Global Supply Chain Visibility and Efficiency

Yamaha Motor Co., Ltd. (Yamaha Japan) and its U.S. subsidiary, Yamaha Motor Corporation, USA (Yamaha USA), today announced a strategic partnership with Shippeo, a leading provider of real-time transportation visibility solutions. Shippeo will provide Yamaha with superior visibility and predictive insights across its entire global supply chain, encompassing ocean, railroad and over the road transportation.

Enhanced Visibility Across the Supply Chain

Yamaha Japan will leverage Shippeo's global network to gain complete coverage of all ocean containers transporting its goods. This includes real-time visibility into all ocean carriers, terminals, ports, and ships, along with predictive arrival estimates. Shippeo's platform ingests data from various sources, including ocean carriers, satellite providers, schedules, and its own proprietary data models, to create a unified and comprehensive view of all shipments.

Seamless Integration and Actionable Insights

Shippeo's solution seamlessly integrates with Yamaha's existing systems, providing both a web-based application and data transmission into Yamaha's SAP solutions. Additionally, Shippeo offers a suite of readily available and configurable business intelligence reports, enabling Yamaha to gain valuable insights across various aspects of their supply chain.

Tangible Value for Yamaha

By partnering with Shippeo, Yamaha expects to achieve significant benefits, including:

Superior customer experience: Enhanced transparency and reliability through real-time visibility and arrival predictions for Yamaha customers, partners, and dealers.

  • Improved operational efficiency: Optimized lead time management, warehouse management, and personnel productivity.
  • Enhanced cost control: Reduced freight spend and related costs through better visibility and proactive management of detention, demurrage, and accessorial fees.
  • Improved transportation vendor management: Data-driven insights to optimize carrier selection and performance based on key metrics like on-time delivery and shipment accuracy.

“We are truly excited about this new strategic partnership with Shippeo and the benefits that it will most certainly bring to easing our Global Supply Chain challenges, simply from providing more seamless administrative and global visibility, “said Isamu “Sam” Kuru of Yamaha Motor Company Japan’s logistics Division. “The benefits to both our distributors and ultimately our Yamaha dealerships and business to business partners and end users will prove invaluable to our entire company.”

"It's an honor to partner with an industry pioneer like Yamaha Motor Company," said Christopher Mazza, SVP International Growth at Shippeo. "Our leading real-time visibility solution empowers Yamaha to deliver exceptional value to their customers and end users by offering superior visibility and actionable insights across all transport modes. This will enhance the resilience of Yamaha's global supply chain operations, ensuring enhanced transparency and reliability."

About Yamaha Motor Corporation, USA

Yamaha Motor Corporation, USA (YMUS), is a recognized leader in the outdoor recreation industry. The company's ever-expanding product offerings include Motorcycles and Scooters, ATV and Side-by-Side vehicles, Snowmobiles, WaveRunner Personal Watercraft, Boats, Outboard Motors, Outdoor Power Equipment, Power Assist Bicycles, Golf Cars, Power Assist Wheelchair Systems, Surface Mount Technology (SMT) and Robotic Machines, Unmanned Helicopters, Accessories, Apparel, Yamalube products, and much more. YMUS products are sold through a nationwide network of distributors and dealers in the United States.

YMUS has a corporate office in California, two corporate offices in Georgia, facilities in Wisconsin and Alabama, and factory operations in Tennessee and Georgia. Additional U.S.-based subsidiaries include Yamaha Marine Systems Company (YMSC) with divisions Bennett Marine (Florida), Kracor Systems (Wisconsin) and Siren Marine, Inc. (Rhode Island), Skeeter Boats (Texas), with division G3 Boats (Missouri), and Yamaha Precision Propeller (Indiana).

About Shippeo

Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport.

Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Arlanxeo, Barilla, Birra Peroni, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, DP World, Evonik, Fujifilm, Jaguar Land Rover, Hartmann Group, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, XPO Logistics and Yamaha Motor, trust Shippeo to track more than 50 million shipments per year across 130 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408354099/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye